Viatris Cost of Goods Sold 2012-2026 | VTRS
Viatris annual/quarterly cost of goods sold history and growth rate from 2012 to 2026. Cost of goods sold can be defined as the difference between beginning and ending inventories for tangible products resulting in an expense that reflects production and sales costs.
- Viatris cost of goods sold for the quarter ending March 31, 2026 was $2.360B, a 12.74% increase year-over-year.
- Viatris cost of goods sold for the twelve months ending March 31, 2026 was $9.553B, a 5.57% increase year-over-year.
- Viatris annual cost of goods sold for 2025 was $9.286B, a 1.87% increase from 2024.
- Viatris annual cost of goods sold for 2024 was $9.116B, a 1.42% increase from 2023.
- Viatris annual cost of goods sold for 2023 was $8.988B, a 7.96% decline from 2022.
|
Viatris Annual Cost of Goods Sold (Millions of US $) |
|
|---|---|
| 2025 | $9,286 |
| 2024 | $9,116 |
| 2023 | $8,988 |
| 2022 | $9,766 |
| 2021 | $12,311 |
| 2020 | $8,149 |
| 2019 | $7,603 |
| 2018 | $7,432 |
| 2017 | $7,125 |
| 2016 | $6,380 |
| 2015 | $5,213 |
| 2014 | $4,192 |
| 2013 | $3,869 |
| 2012 | $3,888 |
| 2011 | $3,566 |
|
Viatris Quarterly Cost of Goods Sold (Millions of US $) |
|
|---|---|
| 2026-03-31 | $2,360 |
| 2025-12-31 | $2,556 |
| 2025-09-30 | $2,388 |
| 2025-06-30 | $2,249 |
| 2025-03-31 | $2,093 |
| 2024-12-31 | $2,313 |
| 2024-09-30 | $2,292 |
| 2024-06-30 | $2,351 |
| 2024-03-31 | $2,159 |
| 2023-12-31 | $2,241 |
| 2023-09-30 | $2,251 |
| 2023-06-30 | $2,310 |
| 2023-03-31 | $2,187 |
| 2022-12-31 | $2,602 |
| 2022-09-30 | $2,330 |
| 2022-06-30 | $2,414 |
| 2022-03-31 | $2,421 |
| 2021-12-31 | $2,795 |
| 2021-09-30 | $2,963 |
| 2021-06-30 | $3,250 |
| 2021-03-31 | $3,303 |
| 2020-12-31 | $2,917 |
| 2020-09-30 | $1,814 |
| 2020-06-30 | $1,706 |
| 2020-03-31 | $1,713 |
| 2019-12-31 | $2,104 |
| 2019-09-30 | $1,889 |
| 2019-06-30 | $1,919 |
| 2019-03-31 | $1,690 |
| 2018-12-31 | $2,063 |
| 2018-09-30 | $1,823 |
| 2018-06-30 | $1,846 |
| 2018-03-31 | $1,700 |
| 2017-12-31 | $1,944 |
| 2017-09-30 | $1,809 |
| 2017-06-30 | $1,737 |
| 2017-03-31 | $1,635 |
| 2016-12-31 | $1,933 |
| 2016-09-30 | $1,774 |
| 2016-06-30 | $1,389 |
| 2016-03-31 | $1,284 |
| 2015-12-31 | $1,428 |
| 2015-09-30 | $1,380 |
| 2015-06-30 | $1,364 |
| 2015-03-31 | $1,042 |
| 2014-12-31 | $1,114 |
| 2014-09-30 | $1,072 |
| 2014-06-30 | $1,029 |
| 2014-03-31 | $978 |
| 2013-12-31 | $1,013 |
| 2013-09-30 | $959 |
| 2013-06-30 | $959 |
| 2013-03-31 | $938 |
| 2012-12-31 | $981 |
| 2012-09-30 | $1,009 |
| 2012-06-30 | $985 |
| 2012-03-31 | $913 |
| 2011-12-31 | $887 |
| 2011-09-30 | $917 |
| 2011-06-30 | $904 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $15.685B | $14.300B |
| Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $134.187B | 24.31 |
| HCA Healthcare (HCA) | United States | $110.772B | 17.53 |
| CVS Health (CVS) | United States | $101.670B | 11.75 |
| Elevance Health (ELV) | United States | $68.432B | 10.33 |
| Cencora (COR) | United States | $62.409B | 19.63 |
| Natera (NTRA) | United States | $27.358B | 0.00 |
| Labcorp Holdings (LH) | United States | $21.501B | 15.87 |
| DiDi Global (DIDIY) | China | $18.026B | 15.96 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $14.535B | 0.00 |
| Medpace Holdings (MEDP) | United States | $14.094B | 32.26 |
| BioMerieux (BMXMF) | France | $12.476B | 0.00 |
| Solventum (SOLV) | United States | $11.408B | 10.78 |
| Revvity (RVTY) | United States | $10.039B | 17.71 |
| BrightSpring Health Services (BTSG) | United States | $8.774B | 43.59 |
| Charles River Laboratories (CRL) | United States | $8.667B | 17.09 |
| ICON (ICLR) | Ireland | $8.626B | 8.56 |
| CochLear (CHEOY) | Australia | $8.030B | 0.00 |
| Sonic Healthcare (SKHHY) | Australia | $6.905B | 0.00 |
| HealthEquity (HQY) | United States | $6.586B | 23.20 |
| Bausch + Lomb (BLCO) | Canada | $5.877B | 32.98 |
| GETINGE (GNGBY) | Sweden | $5.626B | 17.96 |
| Avantor (AVTR) | United States | $5.388B | 8.68 |
| PACS (PACS) | United States | $5.304B | 27.44 |
| Caris Life Sciences,�Inc (CAI) | United States | $5.101B | 0.00 |
| Sotera Health (SHC) | United States | $4.380B | 19.95 |
| Alignment Healthcare (ALHC) | United States | $4.188B | 0.00 |
| Concentras Parent (CON) | United States | $2.818B | 16.12 |
| Organon (OGN) | United States | $2.299B | 2.57 |
| Amplifon S.p.A (AMFPF) | Italy | $2.275B | 13.27 |
| Pediatrix Medical (MD) | United States | $1.782B | 11.11 |
| Establishment Labs Holdings (ESTA) | United States | $1.765B | 0.00 |
| GeneDx Holdings (WGS) | United States | $1.746B | 42.28 |
| Surgery Partners (SGRY) | United States | $1.671B | 41.65 |
| Sonida Senior Living (SNDA) | United States | $1.544B | 0.00 |
| Ardent Health (ARDT) | United States | $1.345B | 5.70 |
| Progyny (PGNY) | United States | $1.277B | 25.08 |
| Ryman Healthcare (RYHTY) | New Zealand | $1.240B | 0.00 |
| InnovAge Holding (INNV) | United States | $1.113B | 164.00 |
| Teladoc Health (TDOC) | United States | $0.920B | 0.00 |
| CareDx (CDNA) | United States | $0.822B | 0.00 |
| GoodRx Holdings (GDRX) | United States | $0.750B | 12.17 |
| Enhabit (EHAB) | United States | $0.709B | 25.89 |
| Nutex Health (NUTX) | United States | $0.704B | 11.25 |
| Omada Health (OMDA) | United States | $0.672B | 0.00 |
| QDM (QDMI) | Hong Kong, SAR China | $0.604B | 99.85 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.531B | 0.00 |
| Embecta (EMBC) | United States | $0.524B | 2.92 |
| Charming Medical (MCTA) | Hong Kong, SAR China | $0.497B | 0.00 |
| CryoPort (CYRX) | United States | $0.482B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.435B | 4.70 |
| SBC Medicals (SBC) | United States | $0.426B | 8.47 |
| Forward Industries (FWDI) | United States | $0.375B | 0.00 |
| Strata Critical Medical (SRTA) | United States | $0.349B | 0.00 |
| Agilon Health (AGL) | United States | $0.316B | 0.00 |
| Shoulder Innovations (SI) | United States | $0.309B | 0.00 |
| Oncology Institute (TOI) | United States | $0.304B | 0.00 |
| So-Young (SY) | China | $0.262B | 0.00 |
| LifeMD (LFMD) | United States | $0.166B | 0.00 |
| Biodesix (BDSX) | United States | $0.133B | 0.00 |
| Beauty Health (SKIN) | United States | $0.115B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.091B | 0.00 |
| Park Dental Partners (PARK) | United States | $0.080B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.077B | 0.00 |
| DocGo (DCGO) | United States | $0.051B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.037B | 0.00 |
| Pomdoctor - (POM) | China | $0.031B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.026B | 0.00 |
| OSR Holdings (OSRH) | United States | $0.018B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.015B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.011B | 0.00 |
| Lifeward (LFWD) | United States | $0.010B | 0.00 |
| XWELL (XWEL) | United States | $0.009B | 0.00 |
| Aclarion (ACON) | United States | $0.007B | 0.00 |
| Synergy CHC (SNYR) | United States | $0.007B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.006B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.005B | 0.00 | |
| Co-Diagnostics (CODX) | United States | $0.005B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.005B | 0.00 |
| ISpecimen (ISPC) | United States | $0.004B | 0.00 |
| INVO Fertility (IVF) | United States | $0.003B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.001B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |